Exploratory ctDNA analyses from first-in-human phase I trial of D3S-001 in patients with advanced solid tumor harboring a KRAS G12C mutation

被引：0
|
作者：
Cho, B. C. [1 ]
Shen, Y. [2 ]
Li, Z. [3 ]
Lu, S. [3 ]
Lee, M. A. [4 ]
Song, Z. [5 ]
Park, J. J. W. [6 ]
Lim, S. M. [1 ]
Zhao, J. [7 ]
Richardson, G. [8 ]
Zhang, Y. [9 ]
Zhang, J. [2 ,10 ]
Liu, A. [11 ]
Chen, C. [2 ]
Liu, Y. [2 ]
Rui, H. [2 ]
Chen, J. Q. [2 ]
Wang, A. H. [2 ]
Zhang, J. [2 ,10 ]
Mok, T. S. K. [12 ]
机构：
[1] Yonsei Univ, ABMRC, Med Oncol Dept 501, Seoul, South Korea
[2] D3 Bio Wuxi Co Ltd, Clin Dev Dept, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China
[4] Catholic Univ Korea, Seoul St Marys Hosp, Internal Med Dept, Catholic Med Ctr, Seoul, South Korea
[5] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Clin Trials Dept, Hangzhou, Peoples R China
[6] Macquarie Univ, Fac Med Hlth & Human Sci, Biomed Sci Dept Level 1, Sydney, NSW, Australia
[7] Beijing Canc Hosp, Dept Oncol, Beijing, Peoples R China
[8] Cabrini Malvern Hosp, Oncol Clin Victoria, Szalmuk Family Dept Med Oncol, Malvern, Vic, Australia
[9] Harbin Med Univ, Canc Hosp, Gastroenterol Dept, Harbin, Peoples R China
[10] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Oncol Dept, Shanghai, Peoples R China
[11] Nanchang Univ, Affiliated Hosp 2, Oncol Dept, Nanchang, Jiangxi, Peoples R China
[12] Prince Wales Hosp, Clin Oncol Dept, Li Ka Shing Specialist Clin, Hong Kong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.673
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
640P
引用
收藏
页码：S1642 / S1643
页数：2
相关论文
共 50 条
  • [41] A first-in-human, open-label, phase I trial of daily oral PCLX-001, an NMT inhibitor, in patients with relapsed/refractory B-cell lymphomas and advanced solid tumors.
    Sangha, Randeep S.
    Jamal, Rahima
    Spratlin, Jennifer L.
    Kuruvilla, John
    Sehn, Laurie Helen
    Weickert, Michael
    Berthiaume, Luc G.
    Mackey, John Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [42] First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)
    Ou, Sai-Hong Ignatius
    Janne, Pasi A.
    Leal, Ticiana A.
    Rybkin, Igor I.
    Sabari, Joshua K.
    Barve, Minal A.
    Bazhenova, Lyudmila
    Johnson, Melissa L.
    Velastegui, Karen L.
    Cilliers, Cornelius
    Christensen, James G.
    Yan, Xiaohong
    Chao, Richard C.
    Papadopoulos, Kyriakos P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (23) : 2530 - +
  • [43] Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors
    Falchook, Gerald Steven
    Hong, David S.
    Amin, Hesham M.
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Granda, J. Gabrielle
    Zheng, Hongxia
    Klevesath, Manfred B.
    Koehler, Karola
    Bladt, Friedhelm
    Johne, Andreas
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.
    Hu, Xingsheng
    Zheng, Xin
    Mo, Hongnan
    Cui, Xinge
    Ding, Lieming
    Tan, Fenlai
    Hu, Pei
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [45] First-in-human biomarker-driven phase I TRESR trial of ataxia telangiectasia and Rad3related inhibitor (ATRi) RP-3500 in patients (pts) with advanced solid tumors harboring synthetic lethal (SL) genomic alterations
    Yap, Timothy
    Lee, Elizabeth
    Spigel, David
    Fontana, Elisa
    Hojgaard, Martin
    Lheureux, Stephanie
    Mettu, Niharika B.
    Carter, Louise
    Plummer, Ruth
    Ulanet, Danielle
    Manley, Peter
    Jiang, Ying
    Rosen, Ezra
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [46] Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors.
    Spira, Alexander I.
    Papadopoulos, Kyriakos P.
    Kim, Dae Won
    Parikh, Aparna Raj
    Barve, Minal A.
    Powderly, John D.
    Starodub, Alexander
    Strickler, John H.
    Li, Bob T.
    Oberstein, Paul Eliezer
    Hassan, Faisal
    Yang, Michelle
    Mccleland, Mark
    Lally, Satwant
    Lin, Wei
    Sohoni, Sophia
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 724 - 724
  • [47] Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors
    Day, D.
    Ganju, V.
    Chung, K.
    Si, L.
    Mao, L.
    Aghmesheh, M.
    Hoyer, R.
    Brewin, K.
    Zeng, S.
    Lu, Q.
    Jiang, C.
    Ren, F.
    Wu, X.
    Guo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S625 - S625
  • [48] A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
    de Bono, J. S.
    Lord, S.
    Yap, C.
    Miranda, S.
    Veal, G. J.
    Chandran, K.
    Paschalis, A.
    Peron, C.
    Rekowski, J.
    Gurel, B.
    Paisley, D.
    McGuigan, L.
    Ingram, P. J.
    Kwek, K. Y.
    Halbert, G.
    Westwood, N. B.
    Griffin, A. E.
    Kostaras, L.
    Boyd-Kirkup, J. D.
    Walter, H. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S479 - S480
  • [49] A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours
    de Bono, J. S.
    Lord, S.
    Yap, C.
    Rowinsky, E. K.
    Gandhi, N. A.
    Thakkar, D.
    Ingram, P. J.
    Padmanabhan, N.
    Chandran, K.
    Paschalis, A.
    McGuigan, L.
    Neal, P.
    Paisley, D.
    Walter, H. S.
    Kelly, F.
    Craigan, J.
    Westwood, N. B.
    Halbert, G.
    Boyd-Kirkup, J. D.
    Halford, S. E. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S767 - S767
  • [50] BL-B01D1, a first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic solid tumor: Results from a first-in-human phase 1 study
    Zhang, Li
    Ma, Yuxiang
    Zhao, Yuanyuan
    Fang, Wenfeng
    Zhao, Hongyun
    Huang, Yan
    Yang, Yunpeng
    Chen, Likun
    Hou, Xue
    Zou, Wen
    Ding, Muran
    Yu, Jing
    Zhang, Suoyu
    Wang, Junxian
    Xiao, Sa
    Wang, Hongwei
    Zhu, Hai
    Olivo, Martin Sebastian
    Zhu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345